Business Context and Reporting Period
This Form 6-K, filed on December 13, 2022, by Midatech Pharma PLC (the "Company"), announces a transformative corporate transaction. The Company has entered into an Arrangement Agreement to acquire Bioasis Technologies Inc. ("Bioasis"), a British Columbia corporation. Upon closing, expected in the first quarter of 2023, Bioasis will become a wholly-owned subsidiary, and the Company will be renamed "Biodexa Therapeutics plc." The Company intends to delist from the London Stock Exchange's AIM market and remain listed on NASDAQ.
Key Financial Metrics and Transaction Terms
The filing details a significant capital raise and acquisition structure rather than standard operating financial results for the period.
- Acquisition Consideration: Bioasis shareholders will receive 0.9556 Ordinary Shares (in the form of ADSs) for each Bioasis Share held.
- Capital Raise (The Offering): The Company is conducting a registered direct offering and private placement with a target gross proceeds of at least US$10.0 million.
- Registered Offering: 393,973 ADSs at US$1.00 per ADS.
- Private Placement: 584,082 Unregistered ADSs at US$1.00 per ADS, plus Series A and Series B warrants (10 million ADSs each) and 9,021,945 pre-funded warrants.
- Debt Resolution: The Company will settle Bioasis's payment obligations to Lind Global Macro Fund, LP (principal amount CAD$3,110,000 plus interest) via a combination of cash repayment and the issuance of Unregistered ADSs and Warrants.
- Bridge Loan: The Company expects to loan Bioasis approximately US$750,000 using proceeds from the Registered Offering.
- Transaction Fees: A cash termination fee of US$330,000 is payable under specific termination scenarios. Placement agent fees include 8.0% of gross proceeds in cash, 4.0% in warrants, and a 1.0% management fee.
Note: The filing text does not provide specific revenue, profit, cash flow, or margin figures for Midatech Pharma PLC for the reporting period. Financial data for Bioasis is referenced in attached exhibits but not detailed in the narrative text.
Material Changes and Strategic Shifts
The primary material change is the proposed merger of Midatech Pharma PLC and Bioasis Technologies Inc. This transaction represents a strategic pivot, combining the two entities under a new name, Biodexa Therapeutics plc. Key structural changes include:
- Corporate Name: Change from Midatech Pharma PLC to Biodexa Therapeutics plc.
- Listing Status: Planned delisting from AIM (London) while maintaining NASDAQ listing.
- Board Composition: The post-closing Board will consist of five directors: the CEO, two individuals determined by the Company (expected to be Stephen Parker and Simon Turton), and two determined by Bioasis (expected to be Deborah Rathjen and Mario Saltarelli).
- Equity Structure: Significant dilution is anticipated due to the issuance of shares for the acquisition, the capital raise, and the settlement of existing debt and warrants.
Guidance, Risks, and Contingencies
Outlook and Conditions: The transaction is subject to customary closing conditions, including shareholder approvals from both companies, court approval in British Columbia, and the successful completion of the US$10.0 million Offering. The closing is targeted for Q1 2023.
Risks and Contingencies:
- Termination Risks: The agreement includes termination rights, including the ability to accept a "Superior Proposal," which would trigger a US$330,000 termination fee.
- Regulatory and Market Risks: The transaction depends on regulatory approvals and market conditions. The filing includes updated risk factors (Exhibit 99.6) regarding the Arrangement and the Offering.
- Forward-Looking Statements: The Company cautions that statements regarding the closing date and proceeds are subject to uncertainties and may not be realized.
Investor Verification Checklist
- Verify the final closing date of the Arrangement and the Offering, as the filing only provides an expected timeframe (Q1 2023).
- Confirm the total gross proceeds raised from the Offering to ensure the US$10.0 million minimum condition is met.
- Review the full text of the Arrangement Agreement (Exhibit 10.1) for specific representations, warranties, and undisclosed schedules.
- Examine the Pro Forma Consolidated Financial Statements (Exhibit 99.4) to understand the combined entity's financial position post-transaction.
- Monitor the status of the AIM delisting and the subsequent NASDAQ listing procedures.
- Assess the impact of the new warrant issuances (Series A, Series B, Pre-Funded, and Placement Agent Warrants) on future dilution.